EGFR and breast carcinoma: It downregulated EGFR and p-EGFR levels in MCF-7 cells [155], reduced the phosphorylation of EGFR in MDA-MB-231 (ER−/PR−/HER2−/EGFR+) breast cancer cells [148] and interrupted the association between α6β4 integrin and EGFR by blocking the distribution α6β4 integrin into lipid rafts [142].